Distinct biological impact of dephosphorylation vs. downregulation of p210^Bcr-Abl: Implications for imatinib mesylate response and resistance

References

• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A S, LaRosee P, Muller M C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (571) therapy. Leukemia 2002; 6: 2190–2196
   Web of Science ®Google Scholar
• Lozzio B, Lozzio C. Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leukemia Res 1979; 3: 363–370
   PubMed Web of Science ®Google Scholar
• Dean A, Erard F, Schneider A P, Schechter A N. Induction of hemoglobin accumulation in human K562 cells by hemin is reversible. Science 1981; 212: 459–461
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Blick M, Evinger-Hodges M J, Beran M, Andersson B, Gutterman J U, et al. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer 1988; 62: 1171–1178
   PubMed Web of Science ®Google Scholar
• Avanzi G C, Lista P, Giovinazzo B, Miniero R, Saglio G, Benetton G, et al. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol 1988; 69: 359–366
   PubMed Web of Science ®Google Scholar
• Faderl S, Estrov Z, Kantarjian H M, Harris D, Van Q, Fokt I, et al. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 2001; 21: 3777–3784
   PubMed Web of Science ®Google Scholar
• Estrov Z, Manna S K, Harris D, Van Q, Estey E H, Kantarjian H M, et al. Phenylarsine oxide blocks Interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 1999; 94: 2844–2853
   PubMed Web of Science ®Google Scholar
• Sirard C, Laneuville P, Dick J E. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanism. Blood 1994; 83: 1575–1585
   PubMed Web of Science ®Google Scholar
• Laurent E, Talpaz, Kantarjian H, Kurzrock. The BCR gene and Philadelphia-positive leukemogenesis. Cancer Res 2001; 61: 2343–2355
   PubMed Web of Science ®Google Scholar
• Goldman J. CML yields a few more clues. Blood 2002; 99: 3491
   Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B J, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–104
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• LeCoutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–1766
   PubMed Web of Science ®Google Scholar
• Weisberg E, Griffin J D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–3505
   PubMed Web of Science ®Google Scholar
• Mahon F X, Deininger M W, Schultheis B, Chabrol J, Reiffers J, Goldman J M, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study. Lancet 2002; 359: 487–491
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641–1650
   PubMed Web of Science ®Google Scholar
• Jorgensen H G, Elliott M A, Allan E, Carr C E, Holyoake T L, Smith K D. α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2000; 99: 713–715
   Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Liu H, Arlinghaus R, Aggarwal B, Shishodin S, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677
   PubMed Web of Science ®Google Scholar
• Sun X, Layton J E, Elefanty A, Lieschke G J. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 2001; 97: 2008–2015
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Pierce A, Owen-Lynch P J, Spooncer E, Dexter T M, Whetton A D. P210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene 1998; 17: 667–672
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001; 97: 2846–2853
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, et al. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-κB activation and IκBα phosphorylation. J Biol Chem 2002; 41: 38159–38167
   Google Scholar
• Mayerhofer M, Florian S, Krauth M T, Aichberger K J, Bilban M, Marculescu R, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 2004; 64: 3148–3154
   PubMed Web of Science ®Google Scholar